v3.26.3
ACQUISITIONS AND DIVESTITURES (Tables)
 9 Months Ended
Sep. 26, 2026
Business Combination, Asset Acquisition, Transaction between Entities under Common Control, and Joint Venture Formation [Abstract]  
Schedule of Purchase Price Allocation
The preliminary purchase price allocations were as follows:
PathoQuest SAS(1)
Cambodian NHP Supplier(1)
April 17, 2026January 14, 2026
(in thousands)
Trade receivables$866 $— 
Inventories841 114,688 
Other current assets (excluding cash)2,034 — 
Property, plant and equipment, net2,223 9,858 
Operating lease right-of-use asset, net1,941 — 
Goodwill (2)
46,998 335,906 
Intangible assets, net20,033 — 
Other assets (3)
2,979 282,517 
Deferred revenue(881)— 
Other current liabilities (6,259)(2,414)
Operating lease right-of-use liabilities(1,954)— 
Other long-term liabilities (4)
(1,455)(233,296)
Total purchase price allocation$67,366 $507,259 
(1) Purchase price allocation is preliminary and subject to change as additional information becomes available concerning the fair value and tax basis of the assets acquired and liabilities assumed, including certain obligations. Any additional adjustments to the purchase price allocation will be made as soon as practicable but no later than one year from the date of acquisition. Measurement period adjustments recorded during the period, as well as the related effects on current period earnings, were immaterial.
(2) The goodwill resulting from these transactions is primarily attributable to the potential growth of the Company’s segments from new customers introduced to the acquired businesses or synergies to be realized from acquiring an internal supplier servicing the DSA business and the assembled workforce of the acquirees. With the exception of $102.6 million of goodwill related to the Cambodian NHP Supplier, which will be deductible for tax purposes upon making the remaining deferred payments, goodwill is not deductible for tax purposes.
(3) Other assets acquired resulting from Cambodian NHP Supplier include $283.0 million of biological assets, which will be amortized over an estimated eleven year useful life.
(4) Cambodian NHP Supplier other long-term liabilities include pre-acquisition uncertain tax positions of the seller associated with the acquired assets. In the third quarter of 2026, the acquired reserves, which increased to $246 million after accumulated interest and penalties, were reversed due to a newly enacted tax law clarifying the Company’s legal obligations and completion of certain tax requirements. For the three and nine months ended September 26, 2026, this resulted in recognition of a $201 million tax benefit in Provision (benefit) for income taxes (refer to Note 14 – Income Taxes for further details) and a $45 million benefit in Selling, general and administrative for non-income tax reserves within the unaudited condensed consolidated statements of income.
Schedule of Business Combination, Intangible Asset, Acquired, Finite-Lived
The definite-lived intangible assets acquired were as follows:
PathoQuest SAS
Definite-Lived Intangible Assets(in thousands)
Client relationships$5,085 
Developed technology14,948 
Total definite-lived intangible assets$20,033 
Weighted Average Amortization Life
Client relationships13
Developed technology13
Total definite-lived intangible assets13
Schedule of Disposal Groups, Including Discontinued Operations
As a result of the divestitures, the Company derecognized the net assets of the European Discovery Divestiture and CDMO and Cell Solutions Divestiture as follows:
European Discovery Divestiture
CDMO and Cell Solutions Divestiture
May 22, 2026May 6, 2026
(in thousands)
Assets
Current assets$50,464 $67,330 
Property, plant, and equipment, net 49,522 294 
Operating lease right-of-use assets, net19,083 — 
Goodwill 37,701 — 
Intangible assets, net53,502 — 
Other assets 1,268 14,285 
Total assets$211,540 $81,909 
Liabilities
Current liabilities 37,177 33,709 
Operating lease right-of-use liabilities17,769 23,316 
Long-term liabilities 31,671 2,925 
Total liabilities$86,617 $59,950